The DOI matches its Crossref record.
Multiple Splice Variants of the Human Calcium-independent Phospholipase A2 and Their Effect on Enzyme Activity
Open accessAbstract
Recently, the cloning of a novel Ca2+-independent phospholipase A2 (iPLA2) from Chinese hamster ovary cells as well as from mouse and rat sources containing a C-terminal lipase motif and eight N-terminal ankyrin repeats has been described. In this report we describe the cloning of the human iPLA2 cDNA and its expression in B-cells and show that the iPLA2 gene undergoes extensive alternative splicing generating multiple isoforms that contribute to a novel mechanism to control iPLA2 activity. The full-length cDNA clone encodes a 806-amino acid protein with a calculated molecular mass of 88 kDa. The protein contains a lipase motif, GXSXG, and ankyrin repeats, as described for the hamster and rodent forms of the enzyme but has an additional 54-amino acid proline-rich insertion in the last of the eight ankyrin repeats (residues 395-449). Furthermore, at least three additional isoforms most likely due to alternative splicing were identified. One that is present as a partial cDNA in the expressed sequence tag data base is similar to iPLA2 but terminates just after the lipase active site, and two other isoforms contain only the iPLA2 ankyrin repeat sequence (ankyrin-iPLA2-1 and -2). Ankyrin repeats are involved in protein-protein interactions and because the purified iPLA2 enzyme exists as a multimeric complex of 270-350 kDa, the expression of just the ankyrin-iPLA2 sequence suggested that these may also interact with the iPLA2 oligomeric complexes and perhaps modulate PLA2 activity. Transfection of the human iPLA2 cDNA into COS cells resulted in a substantial increase in calcium-independent PLA2 activity in cell lysate. No activity above background was observed following ankyrin-iPLA2-1 cDNA transfection. However, co-transfection of the ankyrin-iPLA2-1 and the iPLA2 cDNAs resulted in a 2-fold reduction in activity compared with iPLA2 alone. A similar co-transfection of ankyrin-iPLA2-1 cDNA with the cPLA2 cDNA had no effect on PLA2 activity. These results suggest that the ankyrin-iPLA2 sequence can function as a negative regulator of iPLA2 activity and that the alternative splicing of the iPLA2 gene can have a direct effect on the attenuation of enzyme activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The expanding superfamily of phospholipase A2 enzymes: classification and characterization
Six, D. A., & Dennis, E. A. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00105-0 · Cited by 1,358
Dennis, E. A., Cao, J., Hsu, Y.-H., Magrioti, V., & Kokotos, G. (2011) · Chemical Reviews · doi:10.1021/cr200085w · Cited by 1,203
Lauber, K., Bohn, E., Kröber, S. M., Xiao, Y.-J., Blumenthal, S. G., Lindemann, R. K., Marini, P., Wiedig, C., Zobywalski, A., Baksh, S., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00422-7 · Cited by 967
The phospholipase A2 superfamily and its group numbering system
Schaloske, R. H., & Dennis, E. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.07.011 · Cited by 936
Kudo, I., & Murakami, M. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00020-5 · Cited by 757
Lauber, K., Blumenthal, S. G., Waibel, M., & Wesselborg, S. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00237-0 · Cited by 557
PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron
Morgan, N. V., Westaway, S. K., Morton, J. E. V., Gregory, A., Gissen, P., Sonek, S., Cangul, H., Coryell, J., Canham, N., Nardocci, N., et al. (2006) · Nature Genetics · doi:10.1038/ng1826 · Cited by 533
Recent progress in phospholipase A2 research: From cells to animals to humans
Murakami, M., Taketomi, Y., Miki, Y., Sato, H., Hirabayashi, T., & Yamamoto, K. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.12.001 · Cited by 507
Burke, J. E., & Dennis, E. A. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6132-9 · Cited by 431
Properties of the Group IV phospholipase A2 family
GHOSH, M., TUCKER, D., BURCHETT, S., & LESLIE, C. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.05.003 · Cited by 397
Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway
Murakami, M., & Kudo, I. (2004) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00037-7 · Cited by 371
Farooqui, A. A., Ong, W.-Y., & Horrocks, L. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.7 · Cited by 368
Clinical and genetic delineation of neurodegeneration with brain iron accumulation
Gregory, A., Polster, B. J., & Hayflick, S. J. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061929 · Cited by 364
Murakami, M., Kambe, T., Shimbara, S., & Kudo, I. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.3103 · Cited by 348
Characterization of the human patatin-like phospholipase family
Wilson, P. A., Gardner, S. D., Lambie, N. M., Commans, S. A., & Crowther, D. J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600185-jlr200 · Cited by 297
Phospholipase A2s in Cell Injury and Death
Cummings, B. S., McHowat, J., & Schnellmann, R. G. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39138-4 · Cited by 261
Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms
Levi, S., & Finazzi, D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00099 · Cited by 164
Schaeffer, E. L., Forlenza, O. V., & Gattaz, W. F. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1351-0 · Cited by 71
Metadata
- Authors
- Larsson, P. K. A., Claesson, H.-E., & Kennedy, B. P.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1998-01
- Volume
- 273
- Issue
- 1
- Pages
- 207-214
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2027294838
- Cited by
- 216
- References
- 0
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.